EICHOR
● Completed
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Condition: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC) · Sponsor: Merck Sharp & Dohme LLC
About this study
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: * participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 * participants whose tumors express PD-L1 CPS ≥1 * all participants The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to: * EFS in participants whose tumors express PD-L1 CPS ≥10 * EFS in participants whose tumors express PD-L1 CPS ≥1 * EFS in all participants * OS in participants whose tumors express PD-L1 CPS ≥10 * OS in participants whose tumors express PD-L1 CPS ≥1 * OS in all participants
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (170)
| MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691) | Long Beach, California, United States | — |
| Columbus Regional Research Institute ( Site 0047) | Columbus, Georgia, United States | — |
| University of Kansas Cancer Center ( Site 0023) | Westwood, Kansas, United States | — |
| Cancer Center of Kansas ( Site 0058) | Wichita, Kansas, United States | — |
| University Medical Center ( Site 0035) | New Orleans, Louisiana, United States | — |
| Greater Baltimore Medical Center ( Site 0031) | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Center ( Site 0034) | Boston, Massachusetts, United States | — |
| Henry Ford Hospital ( Site 0685) | Detroit, Michigan, United States | — |
| University of Missouri ( Site 0688) | Columbia, Missouri, United States | — |
| Renown Regional Medical Center ( Site 0706) | Reno, Nevada, United States | — |
| Rutgers Cancer Institute of New Jersey ( Site 0695) | New Brunswick, New Jersey, United States | — |
| Weill Cornell Medical College ( Site 0053) | New York, New York, United States | — |
+ 158 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04210115